Document is current
Any future updates will be listed below
-
Authors
Mustafa, Al-Hassan M. https://orcid.org/0000-0002-4453-2573
Petrosino, Giuseppe
Fischer, Marten A. https://orcid.org/0000-0001-8518-9380
Schnöder, Tina M.
Gül, Désirée
Zeyn, Yanira
Hieber, Christoph
Lossa, Johanna
Muth, Sabine
Radsak, Markus P.
Brenner, Walburgis https://orcid.org/0000-0002-1511-6212
Christmann, Markus
Bros, Matthias
Heidel, Florian H.
Krämer, Oliver H. https://orcid.org/0000-0003-3973-045X
- License Information
-
More Information
Article History
Received: 13 November 2024
Revised: 3 July 2025
Accepted: 22 July 2025
First Online: 29 August 2025
Competing interests
: O.H.K. declares paid consultant activity for BASF, Ludwigshafen, Germany, and the patents “The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity”, “Novel HDAC6 inhibitors and their uses”, and “Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors”. The BASF did not influence the study, and its products are not discussed in this work. All the other authors declare no conflict of interests.
